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Objective: It is generally accepted that patients who require biventricular assist device support have poorer out-
comes than those requiring isolated left ventricular assist device support. However, it is unknown how the timing
of biventricular assist device insertion affects outcomes. We hypothesized that planned biventricular assist device
insertion improves survival compared with delayed conversion of left ventricular assist device support to biven-
tricular assist device support.
Methods: We reviewed and compared outcomes of 266 patients undergoing left ventricular assist device or bi-
ventricular assist device placement at the University of Pennsylvania from April 1995 to June 2007. We subdi-
vided patients receiving biventricular assist devices into planned biventricular assist device (P-BiVAD) and
delayed biventricular assist device (D-BiVAD) groups based on the timing of right ventricular assist device in-
sertion. We defined the D-BiVAD group as any failure of isolated left ventricular assist device support.
Results: Of 266 patients who receivd left ventricular assist devices, 99 (37%) required biventricular assist device
support. We compared preoperative characteristics, successful bridging to transplantation, survival to hospital
discharge, and Kaplan–Meier 1-year survival between the P-BiVAD (n ¼ 71) and D-BiVAD (n ¼ 28) groups.
Preoperative comparison showed that patients who ultimately require biventricular support have similar preop-
erative status. Left ventricular assist device (n ¼ 167) outcomes in all categories exceeded both P-BiVAD and
D-BiVAD group outcomes. Furthermore, patients in the P-BiVAD group had superior survival to discharge
than patients in the D-BiVAD group (51% vs 29%, P< .05). One-year and long-term Kaplan–Meier survival
distribution confirmed this finding. There was also a trend toward improved bridging to transplantation in the
P-BiVAD (n ¼ 55) versus D-BiVAD (n ¼ 22) groups (65% vs 45%, P ¼ .10).
Conclusion: When patients at high risk for failure of isolated left ventricular assist device support are identified,
proceeding directly to biventricular assist device implantation is advised because early institution of biventricular
support results in dramatic improvement in survival.
CARDIOPULMONARY SUPPORTC
P
SEarly morbidity and mortality in mechanical circulatory sup-
port device recipients results primarily from multiple organ
failure, postoperative hemorrhage, pulmonary complica-
tions, and thromboembolic events.1-9 Rates of these compli-
cations are significantly higher in patients who require
biventricular support. In fact, right ventricular (RV) failure
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is the most significant risk factor for mortality in left ventric-
ular assist device (LVAD) recipients.9
Numerous investigators have reported poor outcomes in
LVAD recipients with significant RV dysfunction. Santam-
brogio and colleagues10 reported an 85% transplantation
rate among LVAD recipients without RV failure and only
a 25% transplantation rate in LVAD recipients with RV fail-
ure. Dang and associates11 showed similarly poor survival to
transplantation among patients receiving RVADs after
LVADs (35.7%) compared with that seen in LVAD recipi-
ents without RV failure (89.9%). Farrar and coworkers12 re-
ported a 58% transplantation rate with Thoratec BiVADs
compared with a 74% transplantation rate among Thoratec
LVAD recipients. Finally, Kormos and colleagues13 re-
ported a 100% transplantation rate in LVAD recipients
without RV failure, whereas their BiVAD recipients sur-
vived to transplantation in only 40% of cases. These studies
had relatively small sample sizes, with the exception of theardiovascular Surgery c Volume 137, Number 4 971
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SAbbreviations and Acronyms
BiVAD ¼ biventricular assist device
D-BiVAD ¼ delayed biventricular assist device
DBP ¼ diastolic blood pressure
HR ¼ heart rate
LVAD ¼ left ventricular assist device
P-BiVAD ¼ planned biventricular assist device
RV ¼ right ventricular
RVAD ¼ right ventricular assist device
multicenter Thoratec study,12 which was obviously subject
to significant variability in practice and outcomes between
sites.
Clearly, the increased morbidity and mortality in patients
with post-LVAD RV failure mandates preoperative identifi-
cation of patients who require biventricular support. A small
number of studies have attempted to characterize preopera-
tive parameters that can be used to predict which patients
require biventricular assist device (BiVAD) support.10-16
In total, the published literature identifies at least 25 differ-
ent potential predictors of severe RV failure in LVAD recip-
ients, including but not limited to low right ventricular
stroke work index, preoperative mechanical ventilation, in-
creased creatinine values, female sex, and small body sur-
face area. To enhance the understanding of this problem,
we studied our LVAD and BiVAD cohorts at the Hospital
of the University of Pennsylvania to identify preoperative
predictors of BiVAD need. We found and reported that
low cardiac index, low right ventricular stroke work index,
echocardiographic evidence of severe pre–ventricular assist
device RV dysfunction, increased creatinine values, previ-
ous cardiac surgery, and low systolic blood pressure are
independently associated with BiVAD use.17 Although
a widely accepted consensus does not yet exist, these stud-
ies establish that it is possible to preoperatively identify
patients who require biventricular mechanical circulatory
support.
If it is possible to predict which patients require BiVADs,
then it is plausible that early planned institution of biventric-
ular support will result in better outcomes than delaying
insertion of the RVAD. Two studies have reported results
with patients who received planned BiVADs. Magliato
and associates18 showed 59% survival to transplantation
among 17 Thoratec BiVAD recipients, whereas Tsukui
and coworkers19 reported an exceptional 84% transplanta-
tion rate in select patients who received planned BiVADs.
These results represent substantial improvements over
reported outcomes in patients who had delayed conversion
of LVAD to BiVAD support.10-13
The reports by Magliato and associates18 and Tsukui and
coworkers19 lead us to believe that timely institution of bi-972 The Journal of Thoracic and Cardiovascular Surventricular support is the most effective strategy for patients
at risk for LVAD support failure. Unfortunately, neither of
these reports compares planned BiVAD outcomes with un-
planned BiVAD outcomes at their institutions. Accordingly,
we studied our cohort of 266 LVAD recipients, 99 of whom
also required mechanical support of the right ventricle, to
compare outcomes between LVAD, planned BiVAD, and
delayed BiVAD recipients. This represents the largest sin-
gle-institution series to address this question.
We hypothesized that patients at high risk for LVAD sup-
port failure can achieve improved outcomes with early
planned BiVAD insertion as opposed to delayed conversion
of LVAD to BiVAD support.
MATERIALS AND METHODS
Patients
We performed a retrospective review on all patients who underwent
LVAD implantation at the Hospital of the University of Pennsylvania
from April 1995 to June 2007. Patients were assigned to separate LVAD
and BiVAD groups for comparison. Based on the timing of device insertion,
the BiVAD group was further divided into 2 subgroups: (1) preplanned
BiVAD support (P-BiVAD group) or (2) delayed conversion of LVAD to
BiVAD support (D-BiVAD group).
The P-BiVAD group included only patients who were taken to the
operating room with a predetermined plan to place biventricular support
devices. The devices were implanted concurrently, and no attempt to use
isolated LVAD support was made. The D-BiVAD group was defined as
any failure of isolated LVAD support requiring conversion to BiVAD sup-
port. This included patients who had LVADs converted to BiVADs (1)
during 2 separate operations or (2) during the same operation because
they could not be weaned from cardiopulmonary bypass and taken to
the intensive care unit on LVAD support alone. Although these scenarios
differ somewhat, they both represent unplanned conversion of an LVAD
to a BiVAD.
The decision to implant an RVAD was made by the individual cardiac
surgeon in consultation with the heart failure cardiologist. Multiple factors
influenced this decision. In addition to clinical status, preoperative consid-
erations include patient size, transplant eligibility, device availability, and
expected duration of support. At our institution, transplant-ineligible pa-
tients are considered inappropriate for long-term RVAD use. However, if
a brief period of RV support is anticipated, a temporary RVAD can be
used. Furthermore, the choice of LV device influences the use of an RV
device by potentially altering the need for anticoagulation or the patient’s
eligibility for outpatient therapy.
Thirty-seven percent of our cohort required biventricular support. Two
published series report similar or greater proportions of patients who
required BiVADs,12,13 although most series have a smaller percentage. In
our institution all LVAD recipients at risk for RV failure are started on a mil-
rinone infusion and inhaled prostacyclin to optimize the function of the RV
before weaning from cardiopulmonary bypass. If, on weaning from bypass,
the hemodynamic situation is still not satisfactory, we proceed to RVAD im-
plantation. The higher proportion of RVAD use in our cohort is explained
by multiple factors. First, most series report only patients in whom
LVAD support failed and who then required RVAD support, thereby ex-
cluding patients who received preplanned BiVADs. Additionally, our Bi-
VAD cohort might represent a population more likely to require RV
support than those reported in other studies, as evidenced by the high pro-
portion of female subjects (37%), subjects receiving preoperative mechan-
ical ventilation (71%), subjects with an intra-aortic balloon pump (61%),
and subjects requiring extracorporeal membrane oxygenation (21%) in
our cohort.gery c April 2009
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Multiple devices were used throughout the study period. These include
the BioMedicus Perfusion System (Medtronic, Inc, Littleton, Mass), TCI
IP (Thermo Cardiosystems, Inc, Woburn, Mass), TCI VE (Thermo Cardio-
systems), HeartMate XVE (Thoratec Corp, Pleasonton, Calif), Abiomed
BVS-5000 (Abiomed, Inc, Danvers, Mass), Thoratec PVAD (Thoratec),
and HeartMate II (Thoratec). We define the BioMedicus and Abiomed as
short-term devices, whereas the Thoratec PVAD, TCI IP, TCI VE, and
HeartMate ventricular assist devices are defined as long-term devices. In
the BiVAD subcohorts the use of short- and long-term devices was statisti-
cally equivalent, eliminating an inferior device as an explanation for poor
outcomes among the D-BiVAD group.
Data
The study protocol was approved by the Institutional Review Board of
the University of Pennsylvania. Data were collected retrospectively from
the medical records. Preoperative data, including demographics, clinical
factors, hemodynamic parameters, and laboratory values, were entered
into a database. These data were used to establish the baseline characteristics
of the 2 BiVAD groups. Date of device implantation, date of transplantation,
date of initial hospital discharge, current status (alive or deceased), and date
of death were also collected. These data points allowed us to compare sur-
vival to hospital discharge, survival to transplantation, and 1-year and long-
term Kaplan–Meier survival distribution among the LVAD, P-BiVAD, and
D-BiVAD groups. After accrual of data, identifying information was re-
moved from the database, and a unique code number was assigned to
each record.
Statistical Analysis
SAS 9.1.3 software (SAS Institute, Cary, NC) was used to perform sta-
tistical analysis. Preoperative parameters were compared with c2 tests for
categorical variables and unpaired Student t tests for continuous variables.
Patients requiring preoperative mechanical circulatory support were ex-
cluded from analysis of hemodynamic variables.
Survival to hospital discharge and survival to transplantation were com-
pared among the LVAD, P-BiVAD, and D-BiVAD groups by using c2
tests. Kaplan–Meier survival distribution was compared among the 3 groups
by using XLSTAT version 2007.6 statistical analysis add-in software
(Addinsoft USA, New York, NY) for Microsoft Excel.
RESULTS
There were 266 patients who received LVADs at the Hos-
pital of the University of Pennsylvania during the 12-year
study period. Of these, 167 (63%) patients tolerated isolated
LVAD support, whereas 99 (37%) patients required biven-
tricular support. Of the 99 patients who received BiVADs,
71 underwent preplanned BiVAD insertion (the P-BiVAD
group), and 28 underwent delayed conversion of LVAD to
BiVAD support (the D-BiVAD group).
Of the 28 D-BiVAD patients, 14 underwent RVAD inser-
tion during the LVAD operation primarily because of severe
RV failure in the setting of hemodynamic instability with iso-
lated LVAD support. The remaining 14 D-BiVAD patients
underwent RVAD implantation during a later operation pri-
marily because of progressive multiorgan dysfunction result-
ing from severe RV failure. The median time to RVAD
implantation in this subgroup was 2 days. Outcomes in all
parameters were equivalent in these 2 D-BiVAD subgroups.
Results of univariate analysis comparing the P-BiVAD
and D-BiVAD subgroups are shown in Table 1. Of the 35The Journal of Thoracic and CTABLE 1. Univariate comparison of preoperative characteristics
between planned BiVAD and delayed BiVAD recipients
Variable
P-BiVAD
(n ¼ 71)
D-BiVAD
(n ¼ 28)
P
value
Age (y) 52.4  10.9 49.3  13.2 .2787
Sex (% female) 37 39 .8050
Body surface area (m2) 1.92  0.25 1.95  0.29 .7104
Ischemic cardiomyopathy 59 53 .6127
COPD (%) 8 7 .8297
Diabetes (%) 25 29 .7430
Mechanical ventilation (%) 70 71 .9211
Acute myocardial infarction (%) 27 21 .5823
Previous cardiac surgery (%) 38 54 .1587
Severe preoperative RV
dysfunction (%)*
75 68 .4753
Intra-aortic balloon pump (%) 56 71 .1664
Preoperative circulatory
support (%)
20 25 .5626
Nonseparation from
cardiopulmonary bypass (%)
23 21 .9051
Heart rate (beats/min) 100.1  21.6 113.9  22.4 .0299
Systolic blood pressure
(mm Hg)
96.9  17.5 92.2  11.5 .2010
Diastolic blood pressure
(mm Hg)
57.5  12.5 51.2  10.2 .0389
Mean arterial blood pressure
(mm Hg)
70.6  13.0 64.9  9.9 .0565
Central venous pressure
(mm Hg)
22.5  8.2 21.6  6.5 .6824
Pulmonary artery systolic
pressure (mm Hg)
46.0  11.8 41.1  10.2 .1151
Pulmonary artery diastolic
pressure (mm Hg)
26.5  8.7 26.2  7.4 .8793
Mean pulmonary artery pressure
(mm Hg)
33.0  9.0 31.2  7.9 .4278
Cardiac index (L $ min1 $ m2) 1.77  0.44 1.85  0.36 .4774
SvO2 (%) 56.8  13.0 54.5  9.3 .4842
Right ventricular stroke work
index (mm Hg $ L/m2)y
0.195  0.201 0.209  0.178 .8046
LV ejection fraction (%) 15.0  11.9 14.0  17.0 .7601
White blood cell count (109/L) 14.0  7.4 11.5  5.1 .0788
Hemoglobin (g/dL) 11.3  1.9 11.2  2.0 .7989
Platelet count (109/L) 183.9  109.9 165.0  79.5 .3692
International normalized ratio 1.76  0.86 1.87  1.11 .6510
Partial thromboplastin time (s) 56.3  33.7 53.8  32.8 .7500
Creatinine (mg/dL) 2.08  1.39 1.92  1.46 .6271
Total bilirubin (mg/dL) 1.56  1.48 1.85  1.68 .4898
Alanine aminotransferase (U/L) 626.4  1632.8 253.5  687.8 .1993
Aspartate aminotransferase (U/L) 632.2  1732.7 268.7  309.9 .1460
Albumin (g/dL) 2.7  0.6 2.7  0.8 .8395
BiVAD, Biventricular assist device; P-BiVAD, planned biventricular assist device
group; D-BiVAD, delayed biventricular assist device group; COPD, chronic obstruc-
tive pulmonary disease; SvO2, mixed venous oxygen saturation; LV, left ventricular.
*Right ventricular dysfunction was graded as none, mild, moderate, or severe and
was based on the final report of the preoperative echocardiogram. yRight ventricular
stroke work index ¼ (Mean pulmonary artery pressure Central venous pressure)
3 Cardiac index/Heart rateardiovascular Surgery c Volume 137, Number 4 973
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Sparameters compared between the 2 groups, only heart rate
(HR) and diastolic blood pressure (DBP) were significantly
different. Unexpectedly, HR was slightly higher and DBP
was slightly lower in the group that received unplanned Bi-
VADs. This is counterintuitive if one presumes that patients
exhibiting higher HRs and lower DBPs would be considered
more ill and would therefore receive BiVADs in a planned
fashion. Multivariate comparison of the P-BiVAD and D-
BiVAD groups was not performed because of the lack of sig-
nificant preoperative differences between the populations.
Transplant-eligible patients in each of the 3 study groups
were identified by excluding patients who received LVADs
as destination therapy or who successfully recovered from
ventricular assist device support. All other patients were
considered transplant eligible, irrespective of whether they
were ever listed for transplantation. Of 141 transplant-
eligible patients in the LVAD group, 111 (79%) ultimately
underwent transplantation. This proportion was not signifi-
cantly higher than the transplantation rate in the P-BiVAD
group (65% [36/55],P¼ .0539). Expectedly, the 79% trans-
plantation rate in the LVAD group was significantly greater
than the 45% survival to transplantation achieved in the D-
BiVAD group (10/22, P ¼ .0009). Importantly, patients
who underwent planned BiVAD insertion trended toward
better survival to transplantation than patients undergoing
delayed BiVAD insertion (65% vs 45%, P ¼ .1). Survival
to transplantation among the 3 groups is shown in Figure 1.
Survival to hospital discharge (Figure 2) was highest
among the LVAD group (71% [119/167]). This was signif-
icantly higher than survival to hospital discharge in both
the P-BiVAD (51% [36/71], P ¼ .0023) and D-BiVAD
(29% [8/28], P< .0001) groups. Most importantly, when
P-BiVAD patients (51% survival) were compared with
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FIGURE 1. Comparison of survival to transplantation among the left
ventricular assist device (LVAD), planned biventricular assist device
(P-BiVAD), and delayed biventricular assist device (D-BiVAD) groups.974 The Journal of Thoracic and Cardiovascular SuD-BiVAD patients (29% survival), the result remained sta-
tistically significant (P¼ .0459). In a further subgroup anal-
ysis survival to hospital discharge was determined for the
most commonly used devices. When the HeartMate I (TCI
IP, TCI VE, or HeartMate XVE) was chosen as the
LVAD, survival to discharge was 74.4% (87/117 patients)
for isolated LVAD recipients, 71.4% (5/7) for P-BiVAD
patients, and 28.6% (4/14) for D-BiVAD patients. When
a Thoratec was chosen as the LVAD, survival to discharge
was 63.2% (24/38) for isolated LVAD recipients, 56.0%
(28/50) for P-BiVAD patients, and 36.4% (4/11) for D-Bi-
VAD patients. These results further support the assertion
that survival is primarily determined by the initial decision
to implant univentricular or biventricular devices rather
than the choice of device type.
Analysis of Kaplan–Meier 1-year survival distribution
likewise showed the best results in the LVAD group
(65%). When compared with the P-BiVAD group, which
had 48% one-year survival, this result was statistically sig-
nificant (P ¼ .003). One-year survival was lowest in the
D-BiVAD group, at 25%, which was also significantly
lower than that seen in the LVAD group (P<.0001). Impor-
tantly, comparison between the 2 BiVAD groups showed
statistically higher 1-year survival among P-BiVAD patients
(P ¼ .025). Finally, long-term survival distribution curves
(Figure 3) mirrored the findings at 1 year among the 3
study groups (LVAD vs P-BiVAD, P ¼ .014; LVAD vs
D-BiVAD, P< .0001; P-BiVAD vs D-BiVAD, P ¼ .019).
DISCUSSION
Patients who require mechanical circulatory support face
the risk of life-threatening postoperative complications, which
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FIGURE 2. Comparison of survival to hospital discharge among the left
ventricular assist device (LVAD), planned biventricular assist device
(P-BiVAD), and delayed biventricular assist device (D-BiVAD) groups.rgery c April 2009
Fitzpatrick et al Cardiopulmonary Support
C
P
Sthey must overcome to achieve long-term survival. The devel-
opment of severe RV failure after LVAD implantation is a
serious complication, resulting in end-organ dysfunction in
multiple organ systems. Multiorgan failure subsequently
results in dramatically increased mortality in this group.
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FIGURE 3. Long-term survival distribution curves for the left ventricular
assist device (LVAD; A), planned biventricular assist device (P-BiVAD; B),
and delayed biventricular assist device (D-BiVAD; C) groups.The Journal of Thoracic and CThe most effective therapy for these patients is biventric-
ular mechanical support. However, it is now well recognized
that BiVAD recipients have higher morbidity and mortality
rates than LVAD recipients in nearly all categories. Because
destination therapy is generally not an option for BiVAD
recipients, long-term survival among BiVAD recipients is
closely tied to their ability to survive to transplantation or
recover from VAD support.
Fortunately, posttransplantation survival does not appear
to be linked to the use of univentricular or biventricular
preoperative support. Farrar and coworkers12 showed
equivalent posttransplantation survival through hospital
discharge between the Thoratec LVAD and BiVAD recip-
ients, and the Columbia University group has shown that
pretransplantation RVAD support was not a risk factor
for posttransplantation mortality in their cohort.11,14 Addi-
tionally, Magliato and associates18 reported 90% post-
transplantation survival to hospital discharge in planned
BiVAD recipients.
Therefore if cardiac transplantation is the event that equal-
izes survival between LVAD and BiVAD recipients, we
must improve the rate at which BiVAD recipients survive
to transplantation. Because their morbid illness results
from severe biventricular failure, it is logical to assume
that timely restoration of cardiac output will improve the
ability of BiVAD recipients to survive the perioperative pe-
riod. Magliato and associates18 and Tsukui and coworkers19
have reported favorable results in patients who underwent
planned BiVAD insertion; however, the current literature
does not adequately address how the timing of BiVAD
placement affects patient outcomes.
The current study is the largest to directly compare results
at a single institution between planned BiVAD outcomes
and delayed BiVAD outcomes. In addition, no other study
has examined whether unplanned RVAD insertion immedi-
ately after LVAD insertion (during the same operation) has
a deleterious effect on patient outcomes.
Our previous study established that preoperative demo-
graphics, clinical factors, hemodynamic data, and laboratory
values can be used to readily distinguish between patients
who tolerate isolated LVAD support and those who ulti-
mately require biventricular support.17 In the current study
we compared preoperative parameters between P-BiVAD
patients and D-BiVAD patients to determine whether the
D-BiVAD group exhibited characteristics suggesting they
would tolerate LVAD support. Surprisingly, the 2 groups
were nearly equivalent because only HR and DBP showed
statistically significant differences. Additionally, the small
HR increase and DBP decrease observed in D-BiVAD pa-
tients are probably not meaningful clinically. In summary,
patients who require biventricular support can be clearly dis-
tinguished based on preoperative characteristics from those
who tolerate isolated LVAD support. Furthermore, there is
reason to believe that all patients who ultimately requireardiovascular Surgery c Volume 137, Number 4 975
Cardiopulmonary Support Fitzpatrick et al
C
P
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device insertion based on critical analysis of preoperative
data.17
With respect to outcomes, LVAD recipients survived to
transplantation at the highest rate (79%). However,
P-BiVAD patients in our cohort survived to transplantation
in 65% of cases, a result that was not significantly lower
than the transplantation rate in LVAD recipients. This
bridge to transplantation rate among P-BiVAD patients is
at least comparable with, if not better than, rates published
by Morgan and colleagues,14 Magliato and associates,18
and Tsukui and coworkers.19 Similarly, our 45% bridge-
to-transplantation rate among D-BiVAD patients compares
with the poor results in other published series. The fact
that survival to transplantation among P-BiVAD patients
was not significantly higher than that among D-BiVAD
patients is likely due to the small number of transplant-
eligible patients in the D-BiVAD group (n ¼ 22). None-
theless, these results clearly argue in favor of a strategy
of P-BiVAD placement for patients who require biventric-
ular support.
Not unexpectedly, survival to hospital discharge was
highest in the LVAD group (71%). Importantly, P-BiVAD
patients survived to hospital discharge at a significantly
higher rate (51%) than those who had BiVADs placed in
a delayed fashion (29%). This represents a relative in-hospi-
tal mortality reduction of 31% in the P-BiVAD group com-
pared with that seen in the D-BiVAD group. The fact that
survival to hospital discharge was significantly higher
among P-BiVAD patients than among D-BiVAD patients,
even though the transplantation rate was not significantly
different, is explained by the fact that a high proportion of
P-BiVAD patients (23% [16/71]) successfully recovered
from ventricular assist device support and therefore did not
require transplantation.
Survival distribution rates demonstrate similar results.
Kaplan–Meier 1-year survival again was highest in the
LVAD group (65%). Notably, 1-year survival was signif-
icantly higher in the P-BiVAD group (48%) than in the
D-BiVAD group (25%). Again, this represents a 31%
relative risk reduction for 1-year mortality in the P-BiVAD
group compared with the D-BiVAD group. Most impor-
tantly, long-term Kaplan–Meier survival distribution mir-
rored the findings at 1 year. Importantly, if one examines
BiVAD recipients at our institution, those who were appro-
priately identified as requiring biventricular support before
initial ventricular assist device placement survived to hos-
pital discharge and to 1 year at nearly twice the rate as
those who were not initially believed to require BiVADs.
This study therefore provides strong evidence that a strat-
egy of early planned BiVAD insertion for patients who
require biventricular mechanical circulatory support results
in higher transplantation rates and improved long-term
survival.976 The Journal of Thoracic and Cardiovascular SuThe factors that result in the increased mortality in the
BiVAD groups should ideally be determined. Because
ventricular assist device recipients have complications in
multiple organ systems and the definition of these can vary,
it was difficult in this retrospective review to definitively
identify every complication. Nonetheless, reoperation rates
(P-BiVAD, 62% [44/71]; D-BiVAD, 75% [21/28]) and
the need for postoperative hemodialysis (P-BiVAD, 31%
[22/71]; D-BiVAD, 39% [11/28]) were similar between
the BiVAD subcohorts. The majority of reoperations were
attributed to bleeding. In the BiVAD subcohorts patients
who died in the hospital had similar survival time (P-BiVAD:
mean, 20.2 days; median, 15 days; D-BiVAD: mean, 22.4
days; median, 14.5 days). Although many factors were
involved in the survival time of these patients, causes of death
were likewise similar between the BiVAD subcohorts.
Patients who died early after BiVAD placement generally
died of progressive multiorgan dysfunction, whereas those
who survived longer died as a result of infection, stroke,
and debilitation. These facts demonstrate that P-BiVAD
and D-BiVAD patients have similar postoperative complica-
tions, but patients who receive planned BiVADs have a
tendency to survive at a higher rate.
LIMITATIONS
This was a retrospective study performed at a single insti-
tution. The timing of device implantation and the device type
were based on the clinical judgment of the surgeon in con-
sultation with the heart failure cardiologists, as opposed to
a defined protocol. Additionally, there are innumerable fac-
tors that influence the decision to use univentricular versus
biventricular support. Finally, some percentage of RV fail-
ure is related to intraoperative events that might not be pre-
dictable preoperatively. These include lung injury, massive
transfusion, and poor intraoperative RV protection. There
was no way to correct for the presence of these factors in
this study.
CONCLUSIONS
Exceedingly high postoperative morbidity and mortality
present a significant challenge to long-term survival in pa-
tients who require biventricular mechanical circulatory sup-
port. These poor outcomes result primarily from end-organ
dysfunction because of the severity of the biventricular fail-
ure. This study strongly supports a strategy of early planned
institution of biventricular mechanical circulatory support to
improve survival in patients with morbid heart failure. In
fact, with this strategy, it might be possible for patients
who receive planned BiVADs to achieve outcomes compa-
rable with those of isolated LVAD recipients. Furthermore,
this study highlights the importance of establishing widely
accepted criteria to preoperatively identify patients who re-
quire biventricular support so they can receive appropriate
support devices.rgery c April 2009
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